Authorised Therapeutic confirmatory (Phase III) • Recurrent respiratory infections • Recurrent urinary tract infections • Recurrent herpetic infections

A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating the Efficacy of Transfer Factor TFI Treatment by Assessing the Number of New Infections in Subjects with Recurrent Respiratory or Urinary Tract Infections or Recurrent Herpetic Infections Recorded over a Period of 6 Months from Randomization

EU CTIS ID: 2024-516879-32-00

What this study is testing

  • Therapeutic confirmatory (Phase III)

A plain-language read of the study's public EU CTIS listing. The study team confirms the details.

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18-64 years. The study team makes the final eligibility decision.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.